美康生物：计提各项资产减值准备1046.19万元

Company Summary - Meikang Bio announced a provision for asset impairment of 10.46 million yuan, which will be included in the company's profit and loss for the first three quarters of 2025, reducing operating profit by the same amount [1] - The total amount of assets written off by the company is 546,700 yuan, with credit impairment losses already accounted for, meaning the write-off will not impact the profit and loss for the reporting period [1] - For the year 2024, the company's revenue composition is entirely from medical devices, accounting for 100% [1] - As of the report, Meikang Bio has a market capitalization of 4 billion yuan [1] Industry Summary - The A-share market has surpassed 4,000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation and a new "slow bull" market pattern emerging [1]